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Abstract
Animal  venoms  are  rich  sources  of  bioactive  compounds  that  possess  obvious 
pharmacological,  therapeutic,  and/or  biotechnological  values.  A  majority  of  these 
compounds are peptides that mainly target enzymes, membrane receptors, or ion channels. 
These  peptides  are  most  often  in  a  size  range  that  allows  their  production  in  vitro by 
chemical synthesis or genetic engineering. Unfortunately, they rarely display the required 
characteristics  in  terms of  selectivity,  affinity,  stability  and targeting  with  regard to  the 
desired application. In recent years, a number of structural approaches or strategies have 
been developed to improve the intrinsic potential  of venom peptides. They are reviewed 
herein for their effectiveness.
1. Chemical synthesis versus genetic engineering – Pros and cons
In animal venoms, peptide sizes are mainly in the range of 0.4 to 8.0 kDa. This would 
correspond to peptides of ca. 4 to 70 amino acid residues. Because of the intrinsic structural 
complexities of these peptides (different types of fold and 1-5 disulfide bridges), this size 
range implicates that only a fraction of them (< 50-mer peptides) can easily be produced by 
chemical synthesis [17,22]. Longer peptides are more difficult to produce chemically and 
have  generally  required  the  use  of  molecular  biology  techniques  for  their  productions. 
Basically, chemical synthesis has several advantages over genetic engineering, making the 
former approach more appropriate to improve the structural and functional properties of 
peptides  of  interest.  In  particular,  the  possibility  to  incorporate  non-natural  amino  acid 
derivatives or to form non-amide pseudo-peptide bonds is a definite benefit over genetic 
production. Also, the high yields of peptide productions are assets for detailed structural 
analyses and functional characterizations of the peptides. Finally, the production of peptides 
for therapeutic purposes is less cumbersome when a chemical approach is chosen over a 
genetic one. Indeed, safety, reproducibility, and lack of cell contaminants clearly argue in 
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favor of chemical synthesis. In fact, the vast majority of studies relating structure-function 
analyses are based on peptides produced by chemical synthesis.
2. Peptide improvement requires solid basic knowledge on the lead peptide properties
For valuable strategies of peptide improvement, one needs to know the peptide target(s), 3-
D structure, functional effect(s), and specific application(s) pursued. With uncharacterized 
venom  peptides,  identification  of  actual  target(s)  is  generally  a  difficult  task. 
Pharmacological  profiling  using  well  defined  screening  approaches  often  reveals  that 
peptides recognize several targets (e.g., different ion channel types) or may be derived for 
multiple applications. From pharmacological studies, useful information can be gained that 
includes peptide affinity for its target(s), selectivity profile, and mode of action. Gathering 
structural data is an essential step in defining the interacting surfaces of both the peptide and 
its target(s).  In most cases, venom peptides are readily amenable to  1H-NMR-based 3-D 
structure  determination.  Alternatively,  computer-assisted  molecular  modeling  is  an 
interesting route that can be used for peptide structural analysis provided that appropriate 3-
D structures of related compounds are available from databases to serve as templates. The 
accurate structural determination of the peptide’s target(s) or, at least, of its binding site(s) is 
a  considerably  more  difficult  challenge.  Although  this  condition  is  not  always  met 
satisfactorily, it is clearly beneficial for the design of novel and more potent peptide analogs. 
Structural information, from both peptide and target, allow more sophisticated analyses that 
include  in  silico molecular  docking  simulations.  From the  most  energetically  favorable 
docking solutions, relevant hypotheses can be drawn on the characteristics of the interacting 
surfaces  involved.  These  can  then  be  verified  experimentally  by  using  complementary 
mutagenesis  of  the  peptide  and its  target(s),  leading  to  a  precise  view of  the  peptide’s 
structural and functional properties [11].
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3. Design of novel peptide analogs by selective residue substitution(s)
This  method  is  largely  employed to  obtain  novel  analogs  with  unique  pharmacological 
properties,  or  to  pursue  detailed  structure-function  studies.  It  represents  the  method  of 
choice to address whether or not certain amino acid residues from the peptide are involved 
in target recognition and binding. It also allows a precise mapping of the peptide interacting 
surface, provided that the substituted residues do not alter the global peptide conformation. 
Generally, residue substitutions are made on a systematic basis, using the alanine-scanning 
approach. By this method, the contribution of scorpion toxin functional dyads to K+ channel 
blockage  was  experimentally  investigated  [4,18].  Mutation  of  amino  acid  residues  also 
represents  a  powerful  strategy  to  improve  the  pharmacological  value  and  therapeutic 
potential of a particular peptide. Two general strategies can be envisioned. First, substituting 
amino acid residues within the peptide active site. This strategy can be used to increase the 
affinity of the peptide towards one specific target, or for improving its selectivity profile 
(similar or increased affinity for one target, but decreased affinity towards one or several 
other targets) [23], or both [1]. Second, substituting amino acid residues outside the peptide 
active site. This strategy may generate more subtle variations in peptide pharmacological 
properties, although in a more unpredictable manner. Indeed, it is expected that amino acid 
residue substitutions outside the active site should slightly alter the peptide’s interacting 
surface.  Stronger  conformational  changes  are  expected  from  substitutions  that  target 
residues key for a proper peptide folding. For instance, it has been shown that single residue 
mutations in scorpion maurotoxin can affect its pattern of disulfide bridging and, hence, its 
conformation and pharmacology [9]. Apart from acting on peptide affinity and selectivity by 
substituting natural amino acid residues by others, one can also act on peptide stability (e.g., 
sensitivity  to  proteases)  by using non-natural  residues for  the substitutions  instead.  It  is 
worth  mentioning,  however,  that  a  similar  protease  resistance  can  also  be  acquired  by 
selective  substitutions  based  on  natural  amino  acid  residues  only.  Owing  to  the 
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conformational change of the peptide that is potentially induced by residue substitution, it is 
wise to gain insight of the structural features of each analog designed, produced and tested 
for bioactivity (e.g., 3-D solution structure determination by  1H-NMR, circular dichroïsm 
analysis,  molecular  modeling).  Combined with  docking  simulation  experiments  of  these 
analogs over their targets, all the data gathered should be of value for a still more rational 
design  of  novel  more  potent  and/or  selective  peptide  analogs  by  an  iterative  feedback 
information process.
4. Benefits of size reduction in peptides
Since many large peptides (> 50-mer) are not readily amenable to chemical production, it 
may appear attractive to reduce their size without compromising on their pharmacological 
value.  Unfortunately,  this  strategy  has  seldom  been  used  and  too  little  information  is 
available  from the  literature  to  reasonably  draw a  conclusion  about  their  effectiveness. 
However,  some remarks  may be  pertinent.  Size  reduction  of  peptides  may be  used  for 
delineation  of  their  pharmacophore(s).  Similarly,  it  may prove useful  for  restricting  the 
peptide  selectivity  profiles.  This  approach  would  certainly  be  beneficial  in  terms  of 
production costs and should bypass the complex use of a genetic production strategy. In the 
case of venom peptides, one would expect that such a strategy should severely decrease the 
pharmacological  potencies  of  the  resulting  low mass  analogs  since  the  integrity  of  the 
various toxin folds characterized so far, that would presumably be affected by peptide size 
reduction,  is  required  for  the  correct  spatial  distribution  of  functionally  key amino acid 
residues [17]. However, this strategy might be particularly valuable for peptides presenting 
small pharmacophores, and thus less susceptible to alteration of the active site conformation 
by peptide size trimming.
5. Relevance of chimera and labeling approaches
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Structure-activity relationship studies have demonstrated that a given venom peptide can be 
active on several targets (large selectivity profile) through different interacting surfaces. The 
existence of a variety of folds in venom peptides [17] allows the occurrence of distinct 
relative  localizations  of  the  active  interacting  surfaces  [21].  For  instance,  it  has  been 
documented that scorpion toxins generally fold according to the α/β  architectural motif (an 
N-terminal helical structure connected by disulfide bridges to a C-terminal antiparallel, two- 
or three-stranded,  β-sheet structure) [20]. Many of these scorpion venom peptides act on 
voltage-gated K+ (Kv) channels through interacting surfaces primarily involving their  β-
sheet structures, whereas they may interact with small conductance Ca2+-activated K+ (SK) 
channels through opposite interacting surfaces that implicate their helical structures. Given 
the fact that interacting surfaces of some venom peptides (with enlarged target specificity) 
are  associated  with  residues  of  specific  secondary  structures,  it  may  be  worth  using  a 
chimera  approach  to  produce  peptide  analogs  with  either  enlarged  or  restricted 
pharmacological profiles. A representative example of such an approach was provided with 
a chimera made by the N-terminal helical region of maurotoxin and the C-terminal β-sheet 
region of HsTx1 [19]. In this case, a “gain of function” was obtained since the chimera 
acquires the activity of maurotoxin on SK channels while preserving the pharmacological 
profile of HsTx1 on Kv channels. Conversely, a “loss of function” can be attributed to this 
chimera since the activity of maurotoxin on a specific Kv channel subtype is lost. The cited 
approaches relate to change in peptide selectivity (enlargement or restriction). Of note, the 
chimera approach can tentatively be used to modulate peptide affinity towards a particular 
target without altering the initial pharmacological profile. This was successfully experienced 
using a chimera of butantoxin and maurotoxin in which the addition of the 9 N-terminal 
residues of butantoxin to the 31 C-terminal residues of maurotoxin provides some additional 
molecular contacts for the interaction with Kv1.2 channel (pharmacophore enlargement), 
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thereby enhancing peptide affinity for this channel subtype [15].
Other  technical  applications  are  worth  mentioning.  First,  peptides  can  be  modified  for 
tracking  purposes.  Tracking  can  be  useful  for  the  determination  of  peptide  tissue 
distribution,  sub-cellular  receptor  localization,  or  classical  binding  experiments.  For 
example,  such  an  “add-on”  function  has  proven  valuable  for  demonstrating  the  cell-
penetration  ability  of  maurocalcine,  a  venom peptide  acting  on  intracellular  ryanodine-
sensitive Ca2+ channels [7]. Site-directed chemical modifications of peptides, by labeling 
with fluorescent derivatives or radioactive materials (e.g., 125I), or biotinylation, are routinely 
used  for  binding  experiments.  Second,  venom  peptides  can  be  derived  to  become 
multifunctional. Chemical coupling to other molecules, such as antibodies or independent 
functional  domains,  may  represent  an  interesting  strategy  for  novel  types  of  “gain  of 
function”, including cell targeting, cell toxicity, cell labeling, cell delivery of compounds, 
etc.  Unfortunately,  these  research avenues  are  still  largely unexploited and their  add-on 
values under-evaluated.
6. Strategies implying a change in the pattern of half-cystine pairs
Venom peptides are often highly reticulated structures. It has been evidenced that disulfide 
bridges contribute to the acquisition and stability of the various peptide folds. Secondary 
structures are frequently connected to each other by at least one disulfide bridge. The pattern 
of  a  half-cystine  connection  is  also  crucial  for  the  correct  spatial  distribution  of  the 
functionally key amino acid residues from the peptide interacting surfaces. Strategies based 
on the pattern of half-cystine pairs can be classified into three categories. The first one aims 
at increasing the number of disulfide bridges. The extra half-cystine pair might decrease 
peptide flexibility and, possibly, that of the interacting surfaces, provided that the additional 
disulfide  bridge  is  inserted  in  an  appropriate  location  within  the  peptide  amino  acid 
sequence. In turn, a reduced flexibility may lessen peptide adaptability to their target(s) and 
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one may expect a greater pharmacological selectivity for the analogs designed this way. 
However, an experimental validation of this approach is still needed. In contrast, the second 
strategy relies on a reduction in the number of peptide half-cystine pairs instead; a strategy 
that  may  conceivably  increase  peptide  flexibility  thereby  potentially  affecting  its 
pharmacological behavior. In both cases, adding or removing a disulfide bridge may have 
consequences for the pattern of other half-cystine pairs, therefore highlighting the need for a 
careful structural characterization of the analogs. The third strategy relies on a change in the 
pattern of disulfide bridges within the peptide (with or without variation in the number of 
half-cystine pairs). Enforcing new disulfide bridge arrangements in a peptide is an effective 
way to alter the conformation of its pharmacophore(s) and, hence, its pharmacology. This 
strategy has been applied twice for the scorpion maurotoxin. By replacing two half-cystine 
residues  belonging  to  two  different  disulfide  bridges,  a  novel  three-disulfide-bridged 
maurotoxin  analog  was  produced  in  which  the  third  half-cystine  pair  was  unique.  This 
analog  still  folded along the common  α/β  architectural  motif  of  scorpion toxins,  while 
presenting a new selectivity towards Kv channels [8]. Also, by using an innovative strategy 
of chemical synthesis, a four-disulfide-bridged maurotoxin variant was produced in which 
the two last bridges were differently arranged as compared with native maurotoxin (although 
half-cystine pairings  are  similar  to  those found in other  toxins from the same structural 
family).  Again, for this  analog, the common architectural  motif  was maintained, but the 
change in disulfide bridge pattern was accompanied by changes in pharmacology [16].
It  is  worth  mentioning  that  removal  of  all  half-cystine  pairs  from  a  reticulated  venom 
peptide - in the cases where it has been studied - abolishes peptide bioactivity, suggesting 
that the presence of all disulfide bridges are required for the maintenance of peptide fold. 
This property has  been taken into consideration for peptide-based immunizations  during 
vaccination  programs,  with  the  aim  of  neutralizing  the  toxicity  of  properly  folded  and 
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reticulated toxins [10,24].
7. What about the dipole moment of venom peptides?
Many venom peptides exhibit a marked electric charge anisotropy. A formal representation 
of this anisotropy is  given by the peptide dipole moment.  It  has been proposed that the 
dipole moment guides and orients the peptide towards its target(s), thereby being key for 
peptide specificity [3]. Although the concept is attractive by itself, it remains to be supported 
experimentally. In fact, the main flaw of this concept is that it is somehow incompatible 
with the existence of several interacting surfaces, which are sometimes located on opposite 
faces of the peptide (e.g. activity of maurotoxin on both SK and Kv channels involving 
opposite  faces).  Noteworthy,  the  noticeable  charge  anisotropy  of  venom  peptide 
maurocalcine,  which possesses a highly basic face, is  likely to contribute to its singular 
ability to translocate into cells where the peptide acts [7]. This property is shared with other 
cell-penetrating, structurally-unrelated, peptides such as Tat and penetratin [13].
8. Functional derivation of venom peptides: a search for new applications
Venom peptides exhibit a great variety of folds. In the case of animal toxins acting on ion 
channels, up to 14 different types of fold were identified [17]. Along with other favorable 
characteristics, such as small size and high stability, diversity of fold can advantageously be 
used for a functional derivation of venom peptides. Indeed, active sites of venom peptides 
can be substituted by functionally unrelated pharmacophores of biological value to benefit 
of the gainful peptide characteristics. For example, the CD4 binding surface for the HIV-1 
gp120  envelope  glycoprotein  has  been  successfully  transferred  into  the  structure  of  a 
scorpion toxin possessing the  α/β  scaffold [12]. This approach leads to the production of 
interesting anti-HIV compounds with demonstrated efficacies in vitro. Venom peptides with 
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novel  pharmacophores  represent  new tools  for  biological,  biotechnological  and  medical 
applications.  A  therapeutic  development  may  also  be  envisioned  in  case  the  novel 
compounds possess the appropriate drug properties.
Other types of functional derivation can be achieved that are not necessarily based on the 
replacement  of  the peptide pharmacophore  by an exogenous one.  In  that  case,  different 
properties of the peptide are derived, such as cell targeting, receptor recognition, membrane 
translocation, nucleic acid binding, etc. It is worth noting that, in some cases, it is mandatory 
to eliminate the original pharmacological activity of the peptide to prevent some unwanted 
side  effects.  For  instance,  the  pharmacological  activity  of  maurocalcine  on  intracellular 
ryanodine-sensitive calcium channels can be suppressed [6] in order to use only its cell-
penetration  property  for  the  cell-entry  of  larger  non-membrane  permeable  compounds, 
including whole proteins [7]. In other cases, structures of venom peptides can be modified to 
properly target toxins to a given cell type in vivo. Such a strategy has been developed in the 
case of immunotoxins, in which a toxin is coupled to a cell-targeting ligand or antibody. The 
main focus of the immunotoxin approach is targeted cancer therapy [14]. So far, bacterial 
and plant toxins have been used, but the technique could prove valuable with animal toxins.
9. Improving peptide stability
Since the ever-increasing interest in studying animal venom peptides is related to 
their  potential  use in  therapeutics,  it  appears  suitable  to  optimize  their  stability  in  vivo. 
Several methods can be used to improve peptide stability. Among them, one can mention: (i) 
amino acid residue substitution(s) aimed at protecting the peptide from proteolytic cleavage. 
Residue  replacement(s),  which  should  not  alter  the  pharmacophore  properties,  can  be 
achieved using L-, D-, or non-natural amino acid residues (including residues modified on 
their side-chains). (ii) A selective chemical modification of the peptide (e.g. changing the 
nature of the N- (acetylation) [5] and/or C-terminal extremities (amidation, addition of a 
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specific group such as a fatty acid). Such a strategy may also be valuable for improving the 
pharmacological  characteristics  of  a  given  peptide,  as  shown  in  the  case  of  ShK  sea 
anemone toxin in which grafting of a phosphotyrosine moiety at the N-terminus enhances its 
selectivity profile towards the Kv1.3 potassium channel [2]. (iii) The replacement of natural 
peptide bonds by pseudo-peptide bonds during chemical synthesis (e.g., CO-NH by NH-CO, 
or  CH2-CH2,  or  CO-CH2,  etc).  (iv)  Cysteine-based  cyclization  of  the  peptide.  These 
modifications, which might, by themselves, be detrimental to peptide biological properties, 
should be attempted only to overcome specific problems, such as short peptide half-life, 
poor peptide stability and/or solubility, and inadequate tissue distribution. Of note, although 
peptide modifications have been used in the development of several therapeutically useful 
peptides, it has seldom been put into application for venom peptides. Apart from chemical 
modifications of the peptides, it is also possible to act on peptide stability by using specific 
delivery systems (liposomes, nanoparticles, glycan polymers, hydrogels). The latter do not 
belong to structure-function strategies and thus will not be developed further.
10. Concluding remarks
Despite the richness in biologically active venom peptides, they rarely come with the desired 
set of characteristics. A rationale structure-function strategy is therefore a key step to obtain 
a  valuable compound for  any given application.  Strategies  are  now numerous  and have 
proven to  be efficient  to  reach these goals.  The choice  of  a  particular  strategy actually 
depends on the peptide biological properties that one seeks to reinforce, create, or suppress. 
Not all strategies are equivalent and, sometimes, a combination thereof should be used. An 
iterative feedback information process is  often required,  which combines the benefits  of 
several  approaches,  to  generate  compounds  with  the  appropriate  set  of  requisite 
characteristics.  Combined  strategies  will  prove  valuable  for  the  future  development  of 
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venom peptide-derived drugs in the treatment of specific human diseases.
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